萨特利珠单抗治疗复发高风险抗髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体相关疾病1例  

Analysis of A Case of Satralizumab in the Treatment of Disease Associated with Anti-myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody at High Risk of Relapse

作　　者：王倩 刘琳琳 矫毓娟 WANG Qian;LIU Lin-lin;JIAO Yiu-juan(Department of Neurology,the First Hospitial of Tsinghua University 1 Beijing Huaxin Hospital,Beijing 100016,China)

机构地区：[1]清华大学第一附属医院/北京华信医院神经内科,北京100016

出　　处：《中国临床神经科学》2025年第1期100-105,共6页Chinese Journal of Clinical Neurosciences

摘　　要：目的报道1例萨特利珠单抗治疗复发高风险抗髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体相关疾病(MOGAD)的疗效与安全性数据,为MOGAD患者采用新型生物制剂的探索性治疗提供真实世界数据。方法收集1例12岁的MOGAD女性患儿在多种药物治疗下仍反复复发病例的临床资料,观察患儿在第7次复发时接受萨特利珠单抗治疗后的症状改善情况,评估其复发风险、实验室指标变化及不良反应。结果患儿在第7次复发时启用萨特利珠单抗治疗,期间激素逐渐减量至5 mg·d^(-1),隔日口服。末次随访时保持11个月无复发状态,实验室指标未见异常,治疗期间未上报不良事件。结论MOGAD反复复发,易致残、致死,目前尚无可完全抑制MOGAD复发与进展的有效药物,萨特利珠单抗通过抑制IL-6炎性信号通路,在MOGAD的探索性治疗中发挥了一定的价值,但仍需大样本的研究进一步证实其疗效和安全性。Aim To provide real-world data for the exploratory treatment of patients with myelin oligodendrocyte glycoprotein antibody-associated disease(MOGAD)using novel biological agent by reporting the efficacy and safety of a case of satralizumab in the treatment of disease associated with anti-myelin oligodendrocyte glycoprotein immunoglobulin G antibody at high risk of relapse.Satralizumab,an anti-interleukin-6 receptor monoclonal antibody,has not been reported for adjuvant therapy in patients with MOGAD.Methods Clinical data of a 12-year-old female patient with MOGAD who still relapsed despite multi-drug therapy were collected.Symptom improvement after the treatment with satralizumab at the 7th relapse was observed,and the relapse risk,changes in laboratory indicators and adverse reactions were assessed.Results The patient was treated with satralizumab at the 7th relapse,during which the hormone was gradually reduced to 5 mg·d^(-1) orally every other day,and patient remained relapse-free for 11 months at the last follow-up,no abnormal laboratory indicators were observed,and no adverse events were reported during the treatment.Conclusion Satralizumab has played a role in the exploratory treatment of MOGAD by inhibiting the inflammatory signaling pathway of interleukin-6(IL-6),then large sample size studies are still needed to verify its efficacy and safety.

关 键 词：髓鞘少突胶质细胞糖蛋白抗体相关疾病 复发高风险 萨特利珠单抗 白细胞介素-6 

分 类 号：R742[医药卫生—神经病学与精神病学] R744.53[医药卫生—临床医学]